Results 101 to 110 of about 79,537 (233)

HER2 testing in breast cancer: Opportunities and challenges [PDF]

, 2006
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-25% of breast cancers, usually as a result of HER2 gene amplification. Positive HER2 status is considered to be an adverse prognostic factor. Recognition of the role of HER2 in breast
Annette Lebeau, Arnould L, Baselga J, Bast, Bilous M, Carter P, Cho HS, Clynes RA, Cobleigh MA, Connor CS, Crowder RJ, Dandachi N, De Laurentiis M, Di Leo A, Di Loreto C, Goldhirsch A, Gschwind A, Hancock MC, Hanna W, Harari D, Hortobagyi GN, Hudziak RM, Jacobs TW, Kobayashi M, Lebeau A, Lohrisch C, Mass R, Mass R, Molina MA, Mueller-Holzner E, Nagata Y, Osborne CK, Paik S, Piccart MJ, Piccart-Gebhart MJ, Pietras RJ, Pinto AE, Revillion F, Romond EP, Ross JS, Seidman AD, Sliwkowski MX, Tanner M, Taucher S, Yakes FM, Yarden Y   +45 more
core   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, Volume 20, Issue 5, Page 1185-1201, May 2026.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, Volume 20, Issue 5, Page 1323-1346, May 2026.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

In Vitro and in vivo anti-tumoral effects of the flavonoid apigenin in malignant mesothelioma [PDF]

, 2017
Malignant mesothelioma (MM) is a tumor arising from mesothelium. MM patients' survival is poor. The polyphenol 4',5,7,-trihydroxyflavone Apigenin (API) is a "multifunctional drug". Several studies have demonstrated API anti-tumoral effects.
Andrea Modesti, Andrea Modesti, Enrica Di Stefano, Erika Zago, Ginevra Berardi, Giovanni Vanni Frajese, Gloria Taffera, Ilaria Tresoldi, Laura Masuelli, Maria Gabriella Giganti, Monica Benvenuto, Roberto Bei, Roberto Bei, Rosanna Mattera   +13 more
core   +2 more sources

Ligand-induced ErbB receptor dimerization [PDF]

Experimental Cell Research, 2009
Structural studies have provided important new insights into how ligand binding promotes homodimerization and activation of the EGF receptor and the other members of the ErbB family of receptor tyrosine kinases. These structures have also suggested possible explanations for the unique properties of ErbB2, which has no known ligand and can cause cell ...
openaire   +2 more sources

Emerging strategies to target metastasis and therapy resistance in melanoma

Molecular Oncology, Volume 20, Issue 5, Page 1111-1114, May 2026.
Emerging studies propose new approaches to interfere with melanoma progression. In recognition of melanoma awareness month, at Molecular Oncology, we highlight recently published research articles, focusing on novel therapeutic targets driving metastatic spread and outlining different strategies to overcome resistance to BRAF inhibitors and anti‐PD‐1 ...
Amel Aziba
wiley   +1 more source

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer [PDF]

, 2018
Background Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER+) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing ...
A Carracedo, A Subramanian, AH Evans, Allan Thornhill, Alshad S. Lalani, Aradhana Rani, C Trapnell, CK Osborne, CX Ma, Eugene Schuster, FL Chen, Francesca Avogadri-Connors, G Arpino, HJ Burstein, IE Smith, J Baselga, Joanna Nikitorowicz-Buniak, KE Bachman, KE O'Reilly, L Gandhi, LA Martin, LA Martin, Lesley-Ann Martin, LV Sequist, M Arnedos, M Dowsett, Mitch Dowsett, MT Weigel, N Patani, N Simigdala, NA O'Brien, Nikiana Simigdala, R Ribas, Ricardo Ribas, Richard E. Cutler, S Johnston, SC Drury, SN Mohd Nafi, SP Newman, Stephanie K. Guest, Stephen R. Johnston, Sunil Pancholi, T Nagashima, W Luo   +43 more
core   +6 more sources

Deciphering and Targeting the Schwannoma‐Neuron‐Macrophage Crosstalk for the Treatment of Schwannomatosis and Associated Pain

Advanced Science, Volume 13, Issue 26, 8 May 2026.
We established patient‐derived SWN cell lines and orthotopic PDX models that recapitulate patient pain phenotypes, alongside a novel intravital DRG imaging platform to track macrophage infiltration and neuronal pain responses. Using these models, we define HMGB1–CCL2–IL‐6 signaling crosstalk driving pain and identify EGF signaling as a key regulator of
Zhenzhen Yin, Limeng Wu, Yanling Zhang, Yao Sun, Grace Y. Lee, Simeng Lu, Xing Gao, John W. Chen, Sonu Subudhi, William Ho, Chao Zhu, Jun Ren, Gino B. Ferraro, Alona Muzikansky, Anat Stemmer‐Rachamimov, Jianren Mao, Scott R. Plotkin, Lei Xu   +17 more
wiley   +1 more source

Liver: Intrahepatic cholangiocarcinoma [PDF]

, 2009
Review on Liver: Intrahepatic cholangiocarcinoma, with data on clinics, and the genes ...
Aishima, S, Enjoji, M
core   +1 more source

Interaction between ErbB‐1 and ErbB‐2 transmembrane domains in bilayer membranes

FEBS Letters, 2002
The transmembrane domains of ErbB receptor tyrosine kinases are monotopic helical structures proposed to be capable of direct side‐to‐side contact with related receptors. Formation of the resulting homo‐ or hetero‐oligomeric complexes is considered a key step in ligand‐mediated signalling.
Sharpe, Simon, Barber, Kathryn R., Grant, Chris W.M.   +2 more
openaire   +2 more sources